Table 2. Incidence of Lymphoma According to Exposure Group.
| Lymphoma Type | Overall (1 060 336 PY) |
Unexposed to Thiopurines or Anti-TNF Agents (838 611 PY) |
Exposed to Thiopurine Monotherapy (129 743 PY) |
Exposed to Anti-TNF Monotherapy (77 229 PY) |
Exposed to Combination Therapy (14 753 PY) |
|||||
|---|---|---|---|---|---|---|---|---|---|---|
| No. of Events | IR per 1000 PY (95% CI) | No. of Events | IR per 1000 PY (95% CI) | No. of Events | IR per 1000 PY (95% CI) | No. of Events | IR per 1000 PY (95% CI) | No. of Events | IR per 1000 PY (95% CI) | |
| All Patients | ||||||||||
| All lymphoma | 336 | 0.32 (0.28-0.35) |
220 | 0.26 (0.23-0.29) |
70 | 0.54 (0.41-0.67) |
32 | 0.41 (0.27-0.55) |
14 | 0.95 (0.45-1.45) |
| Hodgkin lymphoma | 55 | 0.05 (0.04-0.07) |
30 | 0.03 (0.02-0.04) |
13 | 0.10 (0.05-0.15) |
6 | 0.08 (0.02-0.14) |
6 | 0.41 (0.08-0.74) |
| Non-Hodgkin lymphoma | 281 | 0.27 (0.21 -0.33) |
190 | 0.23 (0.20-0.26) |
57 | 0.44 (0.33-0.55) |
26 | 0.34 (0.21-0.47) |
8 | 0.54 (0.16-0.92) |
| Patients With Incident IBDa | ||||||||||
| All lymphoma | 69 | 0.27 (0.21-0.33) |
48 | 0.24 (0.17-0.31) |
12 | 0.39 (0.17-0.61) |
5 | 0.24 (0.03-0.45) |
4 | 0.79 (0.01-1.57) |
| Hodgkin lymphoma | 13 | 0.05 (0.02-0.08) |
10 | 0.06 (0.03-0.09) |
1 | 0.04 (0.0-0.10) |
0 | 0 | 2 | 0.40 (0.0-0.95) |
| Non-Hodgkin lymphoma | 56 | 0.22 (0.16-0.28) |
38 | 0.19 (0.13-0.25) |
11 | 0.36 (0.15-0.57) |
5 | 0.24 (0.03-0.45) |
2 | 0.40 (0.0-0.95) |
Abbreviations: IBD, inflammatory bowel disease; IR, incidence rate; PY, person-years; TNF, tumor necrosis factor.
a
Patients with incident IBD account for 254 927 PY of follow-up overall: 198 555 as unexposed, 30 698 as exposed to thiopurine monotherapy, 20 637 as exposed to anti-TNF monotherapy, and 5037 as exposed to combination therapy.